<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03561454</url>
  </required_header>
  <id_info>
    <org_study_id>20180335</org_study_id>
    <nct_id>NCT03561454</nct_id>
  </id_info>
  <brief_title>An Investigator Initiated Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft® Axxent® eBx System</brief_title>
  <official_title>An Investigator Initiated Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft® Axxent® eBx System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedStar Franklin Square Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medstar Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MedStar Franklin Square Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single arm, prospective, multi-center, non-randomized study of subjects treated with single&#xD;
      fraction, intra-operative radiation therapy at the time of lumpectomy for early stage breast&#xD;
      cancer.To assess the rate of ipsilateral breast tumor recurrence in subjects treated with the&#xD;
      Xoft Axxent Electronic Brachytherapy System when used for single-fraction, intra-operative&#xD;
      radiation therapy treatment of early stage breast cancer when compared to whole breast&#xD;
      irradiation (WBI) at 5 years of follow-up. The results of this single arm study will be&#xD;
      compared to whole breast irradiation (WBI).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumor recurrence</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Early Stage Breast Cancer</condition>
  <arm_group>
    <arm_group_label>XOFT-Intra-Operative Radiation Therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>XOFT-Intra-Operative Radiation Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IORT</intervention_name>
    <description>Intra-Operative Radiation Therapy</description>
    <arm_group_label>XOFT-Intra-Operative Radiation Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria&#xD;
&#xD;
          1. Subject must have provided written Informed Consent&#xD;
&#xD;
          2. Subject must have biopsy-proven ductal carcinoma in situ (DCIS) or invasive ductal&#xD;
             carcinoma of the breast&#xD;
&#xD;
             a. In addition to invasive ductal carcinoma, allowable invasive carcinomas are: i.&#xD;
             Adenoid cystic (or adenocystic) carcinoma ii. Low-grade adenosquamous carcinoma iii.&#xD;
             Medullary carcinoma iv. Mucinous (or colloid) carcinoma v. Papillary carcinoma vi.&#xD;
             Tubular carcinoma vii. Metaplastic carcinoma viii. Micropapillary carcinoma ix. Mixed&#xD;
             carcinoma&#xD;
&#xD;
          3. Subject must be female ≥ 40 years of age&#xD;
&#xD;
          4. Subject's tumor(s) must be &lt; 3.0 cm in greatest diameter by pre-operative assessment&#xD;
&#xD;
          5. Clinical staging of Subject's tumor(s) must meet AJCC Tumor Classification: Tis, T1 or&#xD;
             T2 (&lt; 3 cm), N0, M0&#xD;
&#xD;
          6. Subject presenting with bilateral breast cancer may be enrolled if BOTH cancers meet&#xD;
             all of the inclusion and none of the exclusion criteria&#xD;
&#xD;
          7. Women of child-bearing potential must have a negative pregnancy test within one week&#xD;
             of IORT treatment&#xD;
&#xD;
          8. Women of child-bearing potential must agree to use adequate contraceptive precautions&#xD;
             (defined as intrauterine devices, surgical contraceptives or a combination of condom&#xD;
             and spermicide) from the time of negative pregnancy test through completion of the&#xD;
             radiation treatment period&#xD;
&#xD;
        General Exclusion Criteria&#xD;
&#xD;
          1. Subject is pregnant or nursing&#xD;
&#xD;
          2. Subject has significant auto-immune disease&#xD;
&#xD;
          3. Subject has a pacemaker present in the field of radiation or quadrant of the breast&#xD;
             cancer&#xD;
&#xD;
          4. Subject has multi-focal breast cancer where the sum of the individual tumor sizes&#xD;
             (greatest diameters) are &gt; 3 cm Subject has multi-centric breast cancer&#xD;
&#xD;
          5. Subject has known lympho-vascular invasion&#xD;
&#xD;
          6. Subject has invasive lobular cancer&#xD;
&#xD;
          7. Subject has undergone neo-adjuvant chemotherapy or neo-adjuvant endocrine therapy for&#xD;
             current breast cancer&#xD;
&#xD;
          8. Subject has a history of recurrent breast cancer in the ipsilateral breast&#xD;
&#xD;
          9. Subject has had previous radiation exposure of the involved breast&#xD;
&#xD;
         10. Subject has BRCA 1 or 2 mutations. Note: Testing will only be required for subjects&#xD;
             presenting with bilateral breast cancer; testing is not required for unilateral&#xD;
             cancers&#xD;
&#xD;
         11. Subject has contraindications for radiation&#xD;
&#xD;
         12. Subject considered by the Investigator to be high-risk for breast conservation surgery&#xD;
             and/or intra-operative radiation therapy&#xD;
&#xD;
         13. Subject has participated in any other clinical investigation that is likely to&#xD;
             confound study results or affect study outcome either at the time of IORT or for 3&#xD;
             months prior to IORT&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maen Farha, MD</last_name>
    <phone>(443) 444-5930</phone>
    <email>maen.farha@medstar.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Janice Fowler</last_name>
    <phone>443-777-6128</phone>
    <email>janice.fowler@medstar.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MedStar Good Samaritan Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maen Farha, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 7, 2018</study_first_submitted>
  <study_first_submitted_qc>June 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2018</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

